$heff's $tation of $tocks & $olid DD

[$heff]

New Economy & Beginner Portfolio Update.. This stock will do well in 2014 in my opinion & is the OTCBB Wild Card for 2014. I plan to follow the smart money here! The goal of LJPC (Lajolla Pharma) is to eventually uplist to a major exchange(Nasdaq) and to get even more investors on board. They currently have an impressive list of backers at $.07 from their recent financing that eliminated a lot of overhang & debt, & poor share structure in the company. The recent investors via restructuring are impressive in: Baker Brothers, Tang Mngmt, RTW Investments, & Boxer Capital Group. Major DD Posts to follow!

Alert..bought LJPC at $.15 in the New Economy & Beginner Portfolio. Expecting significant gains in 2014 in this one. GCS-100, theLJPC lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer.

Two Catalysts..#1) Plan to initiate Phase 1 clinical trial for the treatment of Hepato Renal Syndrome by the end of 2013/early 2014.



#2) La Jolla Pharmaceutical Company Announces Complete Enrollment of Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease - http://yhoo.it/1d6bR6C

Announced that it has completed enrollment of its placebo-controlled, randomized Phase 2 clinical trial of GCS-100 in patients with chronic kidney disease ("CKD"). A total of 121 patients with Stage 3b or 4 CKD were enrolled in the study. The Company expects to announce data on the primary endpoint in April 2014 and the full data package before the end of the second quarter 2014.

LJPC Corporate Highlights


A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease - Full Text View - ClinicalTrials.gov http://1.usa.gov/1drz8xQ

Large Institutional Ownership..with Baker Brothers being one of those owners.




Full Disclaimer.. http://bit.ly/OlN9DB